LONE TREE, Colo., Feb. 13, 2015 (GLOBE NEWSWIRE) -- via PRWEB - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the recent hire of Colin Glennan, CHC as Director of Compliance and Todd Romero as Director of Quality.
Mr. Glennan has over 24 years of compliance, quality and customer service experience in various healthcare organizations. Most recently, he was Compliance Manager for Catamaran Corporation, a pharmacy services company, where he was responsible for compliance with federal, state and health insurance regulations related to Medicare, Medicaid and State Departments of Insurance.
Mr. Romero has 20 years of operations and quality management experience with various healthcare companies. Most recently, he was Director of Operations at AlloSource, a leader in fresh cartilage tissue used for joint repair and skin allografts to help heal severe burns. He has held quality and operations management positions with leading healthcare companies including LABS, Inc., Mesa Laboratories and Terumo BCT.
Thomas Sandgaard, CEO of Zynex stated, "We are pleased to welcome Colin and Todd to the team at Zynex. With Colin's deep compliance background and Todd's strong quality management experience Zynex is well positioned to move ahead as our business continues to improve."
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex's product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex also operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.
For additional information, please visit: http://www.ir-site.com/zynex.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2013.
Contact: Zynex, Inc. 303-703-4906
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/02/prweb12514677.htm